Disproportionality analysis of off-label intravitreal bevacizumab in the FDA Adverse Event Reporting System database
Therapeutic Advances in Drug Safety
Published online on July 28, 2026
Abstract
Therapeutic Advances in Drug Safety, Volume 17, January-December 2026.
Background:Bevacizumab, an anti-vascular endothelial growth factor agent initially approved for cancer treatment, is widely used off-label in retinal vascular diseases; however, this use may carry safety risks, particularly when evidence from controlled ...
Background:Bevacizumab, an anti-vascular endothelial growth factor agent initially approved for cancer treatment, is widely used off-label in retinal vascular diseases; however, this use may carry safety risks, particularly when evidence from controlled ...